Similar Articles |
|
The Motley Fool March 1, 2011 David Williamson |
Glaxo Gets Its Day in Court GlaxoSmithKline and Rite-Aid are taking Abbott's HIV drug pricing to the courts. |
The Motley Fool July 19, 2010 Brian Orelli |
Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so. |
The Motley Fool April 16, 2009 Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
The Motley Fool February 18, 2010 Brian Orelli |
Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues. |
The Motley Fool January 6, 2010 Brian Orelli |
Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data. |
The Motley Fool November 27, 2009 Brian Orelli |
A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence. |
The Motley Fool July 17, 2009 Brian Orelli |
Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson. |
The Motley Fool April 15, 2011 Brian Orelli |
Shedding the Pounds Through Divestiture Glaxo plans to sell 19 OTC products. |
The Motley Fool September 20, 2011 Brian Orelli |
Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell? |
The Motley Fool May 24, 2004 Brian Gorman |
Abbott Labs Stirs Up Criticism With politicians and the public riled up about Medicare, Abbott hiked the cost of an HIV drug. Smart move? |
The Motley Fool September 28, 2009 Rick Aristotle Munarriz |
Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered. |
The Motley Fool August 16, 2006 S.J. Caplan |
Abbott Labs' Latest Leaps Generating increased goodwill while potentially expanding its HIV drug market, together with marking progress in its new vascular stent business, proved to be a potent formula for lifting Abbott's shares early this week. Investors, take note. |
The Motley Fool June 28, 2011 Brian Orelli |
HIV Drug Partnership Gets a Boost Gilead and Johnson & Johnson hook up on a pair of new combo treatments. |
The Motley Fool April 21, 2009 Brian Orelli |
Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply. |
The Motley Fool September 11, 2008 Brian Orelli |
Glaxo's Not Gambling The pharmaceutical's deal for drug developer Cellzome is back-end loaded. |
The Motley Fool June 29, 2010 Brian Orelli |
Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify. |
The Motley Fool July 27, 2011 Brian Orelli |
Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain. |
The Motley Fool August 28, 2009 Brian Orelli |
Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug. |
The Motley Fool August 9, 2011 Brian Orelli |
Some Potential Good News in Biotech The FDA should approve Gilead's Btripla. |
The Motley Fool April 3, 2008 Brian Lawler |
A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs. |
The Motley Fool February 24, 2011 Brian Orelli |
Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%. |
The Motley Fool January 27, 2011 Brian Orelli |
Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade. |
The Motley Fool December 21, 2004 Brian Gorman |
Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients. |
The Motley Fool April 6, 2010 Brian Orelli |
Kill It! Double-Teaming Malaria Malaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome. |
The Motley Fool March 24, 2011 Brian Orelli |
It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors. |
The Motley Fool January 27, 2010 Brian Orelli |
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that. |
The Motley Fool October 17, 2008 Brian Orelli |
Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results. |
The Motley Fool October 28, 2004 Bill Mann |
Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year. |
The Motley Fool June 30, 2009 Brian Orelli |
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. |
The Motley Fool June 30, 2009 Brian Orelli |
Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward. |
The Motley Fool December 17, 2008 Brian Orelli |
A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off. |
The Motley Fool August 10, 2010 Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
The Motley Fool May 21, 2010 Brian Orelli |
Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea. |
The Motley Fool November 13, 2009 Brian Orelli |
Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials. |
The Motley Fool December 18, 2009 Brian Orelli |
2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond. |
The Motley Fool October 21, 2010 Brian Orelli |
Abbott Just Can't Get Any Love Despite meeting or beating analysts' earnings for a streak that stretches balk half a decade, Abbott Labs hasn't been able to get much love from investors. |
The Motley Fool July 29, 2010 Brian Orelli |
Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company. |
The Motley Fool October 20, 2011 Brian Orelli |
Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other. |
The Motley Fool August 4, 2010 Matt Koppenheffer |
How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale? |
The Motley Fool January 21, 2010 Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool January 22, 2009 Brian Orelli |
Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon. |
The Motley Fool April 18, 2008 Brian Orelli |
Big Deal for Small RNAs Glaxo buys into Regulus' microRNA research. |
The Motley Fool January 27, 2011 Brian Orelli |
Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out. |
The Motley Fool May 24, 2011 Brian Orelli |
J&J Approved, but Needs Help From a Friend The HIV combo product is the key. |
The Motley Fool December 31, 2007 Brian Lawler |
Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year. |
The Motley Fool July 17, 2008 Brian Orelli |
Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release |
The Motley Fool April 23, 2009 Brian Orelli |
Hitting the Patent Cliff Early Glaxo is at the front edge of a patent cliff. But that means that when other drugmakers are hurting a few years down the road, Glaxo should be sitting pretty, seeing the fruits of all those partnerships it's investing in now. |
The Motley Fool February 8, 2008 Brian Lawler |
Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper. |
The Motley Fool June 15, 2004 Brian Gorman |
Abbott's Gambit Abbott Laboratories is making a high-stakes stand on drug pricing in a dispute that threatens to make hostages out of the pharmaceutical industry and its investors. |
The Motley Fool February 26, 2010 Brian Orelli |
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. |